Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.45 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 10/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TET3 | O43151 | 1/20 | 0.35 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.35 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23866133 | 0.93 | TEAD1 (0.44) | TEAD1TEAD3CCR2BTKJAK3 | |
| SCHEMBL1629421 | 0.89 | TEAD1 (0.40) | TEAD1TEAD3BTKJAK3 | |
| SCHEMBL14479237 | 0.89 | TEAD1 (0.40) | TEAD1TEAD3BTKJAK3 | |
| SCHEMBL1630022 | 0.89 | TEAD1 (0.40) | TEAD1TEAD3BTKJAK3 | |
| SCHEMBL22431481 | 0.85 | TEAD1 (0.46) | TEAD1TEAD3BTKJAK3CDK7 | |
| SCHEMBL21616252 | 0.81 | TEAD1 (0.43) | TEAD1TEAD3BTKJAK3CDK7 | |
| SCHEMBL20081658 | 0.81 | TEAD1 (0.40) | TEAD1TEAD3BTKJAK3CDK7 | |
| SCHEMBL17426256 | 0.80 | BTK (0.40) | TEAD1BTKJAK3 | |
| SCHEMBL25367056 | 0.79 | CCR2 (0.43) | CCR2JAK3KMT2AMEN1ALDH1A1 | |
| SCHEMBL1628867 | 0.79 | JAK3 (0.41) | TEAD1BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | KJ CHEMICALS CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4435021-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | KJ Chemicals Corporation (JP) | 2024-09-25 | — | — | EP | disclosed |
| CN-118251428-A | Active energy ray-curable composition | 科巨希化学股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-20230391937-A1 | POLYMERIZABLE COMPOSITION, PRODUCT OF POLYMERIZATION OF SAME, AND MOLDED ARTICLE OBTAINED USING THESE | KJ CHEMICALS CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4230664-A1 | POLYMERIZABLE COMPOSITION, PRODUCT OF POLYMERIZATION OF SAME, AND MOLDED ARTICLE OBTAINED USING THESE | KJ Chemicals Corporation (JP) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023090302-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | ＫＪケミカルズ株式会社 | 2023-05-25 | — | — | WO | disclosed |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TEAD1 3166/4885TEAD3 3316/4885CCR2 1484/4885 |
| US-20230391937-A1 | POLYMERIZABLE COMPOSITION, PRODUCT OF POLYMERIZATION OF SAME, AND MOLDED ARTICLE OBTAINED USING THESE | MTR, AHCY, MAT1A | TEAD1 4793/4885TEAD3 4839/4885CCR2 2007/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TEAD1 3166/4885TEAD3 3316/4885CCR2 1484/4885 |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TEAD1 3166/4885TEAD3 3316/4885CCR2 1484/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | TEAD1 114/4885TEAD3 164/4885CCR2 4769/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | TEAD1 3192/4885TEAD3 3346/4885CCR2 1496/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | TEAD1 3942/4885TEAD3 3825/4885CCR2 1483/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | TEAD1 3148/4885TEAD3 3253/4885CCR2 1186/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | TEAD1 114/4885TEAD3 164/4885CCR2 4769/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | TEAD1 3168/4885TEAD3 3319/4885CCR2 1153/4885 |
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | PARP1, CAP1, XRN2 | TEAD1 2946/4885TEAD3 4200/4885CCR2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.